anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

Resolution

Beat collection for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Matching slides 42,534
Current window 31,921-31,950
Pages 1,418
Rows per page 30
Beat: Resolutionclear collectionreset all
18 30 60

Beat

31,921-31,950 of 42,534

filter-aware
09
Includes a Manhattan plot visualization and a zoomed-in regional association plot.23andMe | Investor Presentation Deck | 39 slides · 23andMe
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Logic Chain1 hit
10
The chart is a dot plot showing odds ratios for various phenotypes related to TSLP.23andMe | Investor Presentation Deck | 39 slides · 23andMe
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Logic Chain1 hit
11
The slide demonstrates how 23andMe's genetic data can rescue or refine clinical trial results by identifying biomarkers that stratify patient response.23andMe | Investor Presentation Deck | 39 slides · 23andMe
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Logic Chain1 hit
12
The slide uses a process flow diagram to explain the 'POWER' methodology.23andMe | Investor Presentation Deck | 39 slides · 23andMe
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Logic Chain1 hit
13
23andMe | Investor Presentation Deck | 39 slides23andMe | Investor Presentation Deck | 39 slides · 23andMe
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
14
The slide uses a process flow to demonstrate the predictive power of their genomic platform.23andMe | Investor Presentation Deck | 39 slides · 23andMe
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
15
FxG likely stands for Functional Genomics. The slide uses a process flow diagram to illustrate the R&D pipeline.23andMe | Investor Presentation Deck | 39 slides · 23andMe
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
16
23andMe | Investor Presentation Deck | 39 slides23andMe | Investor Presentation Deck | 39 slides · 23andMe
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
17
23andMe | Investor Presentation Deck | 39 slides23andMe | Investor Presentation Deck | 39 slides · 23andMe
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
18
The slide uses a process flow to illustrate the speed of development, supported by heatmaps and a bar chart showing adverse event profiles.23andMe | Investor Presentation Deck | 39 slides · 23andMe
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
19
23andMe | Investor Presentation Deck | 39 slides23andMe | Investor Presentation Deck | 39 slides · 23andMe
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
20
23andMe | Investor Presentation Deck | 39 slides23andMe | Investor Presentation Deck | 39 slides · 23andMe
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
21
The slide uses a timeline-based pipeline visualization common in biotech investor decks.23andMe | Investor Presentation Deck | 39 slides · 23andMe
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
22
The slide uses a gradient background and serves as a transition to a specific clinical asset.23andMe | Investor Presentation Deck | 39 slides · 23andMe
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
23
Includes survival curves, immunohistochemistry images, genetic association data, and clinical trial data for atopic dermatitis.23andMe | Investor Presentation Deck | 39 slides · 23andMe
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Cost Of Inaction1 hit
24
The slide uses a three-column layout to present pharmacology, mechanism of action (diagram), and clinical development status.23andMe | Investor Presentation Deck | 39 slides · 23andMe
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Cost Of Inaction1 hit
25
The chart uses a swimmer plot format to visualize patient-level treatment duration, dose escalation, and response status.23andMe | Investor Presentation Deck | 39 slides · 23andMe
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Cost Of Inaction1 hit
26
Includes before-and-after CT scan imagery for two lesion types.23andMe | Investor Presentation Deck | 39 slides · 23andMe
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Cost Of Inaction1 hit
27
The slide uses a Gantt-style visualization to map clinical trial milestones (First Efficacy Assessment, 6-mo PFS/OS, 12-mo PFS/OS) against calendar quarters from 2023 to 2026.23andMe | Investor Presentation Deck | 39 slides · 23andMe
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
28
The chart demonstrates superior efficacy of 23ME-00610 over anti-PD1 in stimulating IFNy across multiple cancer types.23andMe | Investor Presentation Deck | 39 slides · 23andMe
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
29
The chart shows statistical significance (p<0.01 and p<0.0001) for the combination therapy.23andMe | Investor Presentation Deck | 39 slides · 23andMe
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
30
23andMe | Investor Presentation Deck | 39 slides23andMe | Investor Presentation Deck | 39 slides · 23andMe
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
31
23andMe | Investor Presentation Deck | 39 slides23andMe | Investor Presentation Deck | 39 slides · 23andMe
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
32
The slide uses a combination of a data table, a biological mechanism diagram, and a summary of clinical validation to support the therapeutic thesis.23andMe | Investor Presentation Deck | 39 slides · 23andMe
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
33
The slide uses a combination of a biological process diagram and a line chart showing tumor cell reduction over time.23andMe | Investor Presentation Deck | 39 slides · 23andMe
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
128
Includes brand logos at the bottom.Zegna | Investor Day Presentation Deck | 150 slides · Zegna
Conference presentation Investor relations Beat · Action1 hit
129
Includes date and company logo.Zegna | Investor Day Presentation Deck | 150 slides · Zegna
Conference presentation Investor relations Beat · Action1 hit
130
Zegna | Investor Day Presentation Deck | 150 slidesZegna | Investor Day Presentation Deck | 150 slides · Zegna
Conference presentation Investor relations Beat · Action1 hit
131
Zegna | Investor Day Presentation Deck | 150 slidesZegna | Investor Day Presentation Deck | 150 slides · Zegna
Conference presentation Investor relations Beat · Action1 hit
132
Zegna | Investor Day Presentation Deck | 150 slidesZegna | Investor Day Presentation Deck | 150 slides · Zegna
Conference presentation Investor relations Beat · Action1 hit